CLDN4 and cancer: It has been shown that zinc finger protein 703 may be a promising target for cancer therapy by directly binding to and transfecting the CLDN4 promoter to activate the expression of CLDN4, inducing EMT and inhibiting the sensitivity of HCC cells to sorafenib (87).